Mateja Pirš
University of Ljubljana
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mateja Pirš.
Mycoses | 2015
Tadeja Matos; Tjaša Cerar; Marina Praprotnik; Uros Krivec; Mateja Pirš
We report the isolation of the emerging fungal pathogen Rasamsonia aegroticola, which belongs Rasamsonia argillacea species complex, from a respiratory sample of a patient with cystic fibrosis. This filamentous fungus, resembling members of a Penicillium and Paecilomyces spp., was identified by morphology and confirmed by DNA sequence analysis. Susceptibility pattern showed high minimal inhibitory concentration of voriconazole and amphotericin B but low minimal inhibitory concentration of caspofungin, micafungin and itraconazole.
Diagnostic Microbiology and Infectious Disease | 2009
Nataša Švent-Kučina; Mateja Pirš; Manica Mueller-Premru; Vesna Cvitkovic-Spik; Romina Kofol; Katja Seme
We report our 1-year experience with modified GeneOhm MRSA assay (formerly IDI-MRSA) for pooled surveillance specimens in low methicillin-resistant Staphylococcus aureus (MRSA) prevalence clinical setting. We have successfully modified the GeneOhm MRSA assay protocol during the specimen preparation step by adding an extra washing step followed by pooling of up to 3 samples per patient (nose, skin, with or without throat) at the lysis step. The sensitivity of the modified assay compared with conventional cultivation was 94.3%, specificity 99.2%, negative predictive value 99.2%, and positive predictive value 94.3%. The modified test is reliable and performed well compared with conventional culture methods in our clinical setting with low-level prevalence of MRSA colonization. Our findings support the use of pooling of the patients samples as a cost-effective way of screening for MRSA colonization.
Infectious diseases | 2015
Lea Papst; Bojana Beović; Katja Seme; Mateja Pirš
Abstract Background: We wanted to determine the time course of colonization with extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (EPE), sites of colonization and risk factors for prolonged colonization with EPE to obtain information for successful infection control measures. Methods: Rectal swab, urine, throat swab and other clinically relevant samples (wound swab, tracheal aspirate and sputum) were obtained from each participant. Sets of follow-up samples and data about potential risk factors for prolonged colonization with EPE were collected every 3 months for 2 years. Multivariate analysis using a logistic regression model was performed to identify risk factors for prolonged colonization. Results: A total of 114 patients were included in the study, 49 completed the 2-year follow-up. In all, 611 sample sets were collected, 309 (50.6%) of which were positive for ESBL. Of the positive sample sets, 90% had a rectal swab positive for ESBL, the throat swab was positive for ESBL in 17.2% of cases and urine in 36.2% of cases; 10% of positive sample sets had negative rectal swabs with EPE isolated from other sites, most often from urine. Immobility was found to be associated with prolonged carriage (≥ 12 months) of EPE. After 2 years, 15/49 (30.6%) patients were colonized with EPE. In 12/49 (24.5%) patients, transient negativity was observed. Conclusions: We found that prolonged colonization with EPE was common, especially in bedridden patients. Transient negative samples were often observed during the course of colonization. In some patients, urine can be the only positive site from which EPE are isolated.
Apmis | 2016
Nataša Švent-Kučina; Mateja Pirš; Romina Kofol; Rok Blagus; Dragica Maja Smrke; Marjan Bilban; Katja Seme
Staphylococcus aureus is among the most important human pathogens. It is associated with different infections and is a major cause of skin and soft tissue infections (SSTIs). The aim of our study was to compare S. aureus isolates associated with SSTIs with isolates obtained from healthy carriers in the Central Slovenia region in terms of antimicrobial susceptibility, genetic diversity by clonal complex (CC)/sequence type, spa type, and by toxin gene profiling. In total, 274 S. aureus isolates were collected prospectively by culturing wound samples from 461 SSTI patients and nasal samples from 451 healthy carriers. We have demonstrated high heterogeneity in terms of CCs and spa type in both groups of isolates. The main clone among SSTI strains was Panton–Valentine leukocidin gene (pvl) positive CC121, whereas the main clone among carrier strains was CC45 carrying a large range of toxin genes. The main spa type in both groups was t091. Pvl was more frequently present in SSTI strains (31.2% SSTI vs 3.6% carrier strains) and staphylococcal enterotoxin C was more frequently present in carrier strains (1.6% SSTI vs 17.0% carrier strains). We have also demonstrated that methicillin‐resistant S. aureus was a rare cause (2.8%) of SSTIs in our region.
Journal of Chemotherapy | 2018
Kristina Nadrah; Mateja Pirš; Samo Kreft; Manica Mueller–Premru; Bojana Beović
Decreasing cephalosporin use was described as an effective intervention in decreasing the incidence of infections caused by Klebsiella pneumoniae harbouring extended-spectrum beta-lactamase (ESBLKP). Due to sustained increased levels of infections caused by ESBLKP, a multifaceted antibiotic stewardship intervention aimed to decrease cephalosporin use was carried out at a large medical unit of a teaching hospital. All cephalosporins except the first-generation were restricted and could only be prescribed after authorization by an infectious disease physician. The use of cephalosporins decreased significantly after intervention. The effect was most prominent for the third-generation cephalosporins (7.9–1.5 DDD/100 OBD). There was an increase in the consumption of piperacillin/tazobactam, carbapenems and fluoroquinolones. In contrast to our expectations the ESBLKP incidence increased, but the changes were not statistically significant. The intervention was successful in controlling the prescribing of cephalosporins, but had no impact on incidence of ESBLKP infections.
International Journal of Antimicrobial Agents | 2017
Daša Stupica; Lara Lusa; Mirijam Nahtigal Klevišar; Sara Terzić; Mateja Pirš; Manica Mueller–Premru; Franc Strle
In patients colonised with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E), the preference for carbapenems (CRBs) over non-CRB antibiotics for empirical therapy of sepsis is questionable from an ecologic perspective. Moreover, how well colonisation predicts an ESBL-E aetiology of infection has been poorly investigated. The purpose of this retrospective observational study was to determine the positive predictive value (PPV) of ESBL-E faecal colonisation for ESBL-E sepsis aetiology and the impact of empirical therapy on treatment outcome. The study included 653 ESBL-E carriers with community-onset sepsis hospitalised at a single medical centre during a 5-year period. The PPV of ESBL-E colonisation for ESBL-E sepsis aetiology was significantly higher (62.6%) when sepsis originated from a urinary tract infection (UTI) than from a respiratory tract infection (24.5%), other known origins (27.1%) or an unidentified origin (21.4%). Among the 653 patients, 177 (27.1%) received CRBs empirically and 476 received non-CRBs, predominantly β-lactam/β-lactamase inhibitor combinations. Although univariate analysis suggested a higher 30-day mortality in the non-CRB versus CRB group (26.7% vs. 19.2%; OR = 1.53; P = 0.049), the estimated association was much smaller and was not significant (OR = 1.11, 95% CI 0.66-1.87; P = 0.68) in the multiple regression analysis adjusted for age, sex, Charlson comorbidity index, and severity, origin or aetiology of sepsis. The subgroup of 240 patients with unidentified sepsis aetiology also did not benefit from empirical CRB treatment. In non-critically ill ESBL-E carriers with community-onset sepsis, CRB-sparing empirical therapy seems appropriate, particularly if sepsis originates from a site other than a UTI.
Nephrology Dialysis Transplantation | 2007
Janez Tomažič; Mateja Pirš; Tadeja Matos; Dušan Ferluga; Jelka Lindič
Acta dermatovenerologica Alpina, Pannonica, et Adriatica | 2014
Mateja Pirš; Borut Jug; Barbara Eržen; Mišo Šabovič; Primož Karner; Mario Poljak; Janez Tomažič
Acta Dermatovenerologica Alpina Pannonica et Adriatica | 2016
Anja Šterbenc; Katja Seme; Liza Lea Lah; Olga Točkova; Tina Kamhi Trop; Nataša Švent-Kučina; Mateja Pirš
Acta dermatovenerologica Alpina, Pannonica, et Adriatica | 2014
Mateja Pirš; Borut Jug; Barbara Eržen; Mišo Šabovič; Primož Karner; Mario Poljak; Janez Tomažič